

NEIL FLANZRAICH

Mr. Flanzraich is the Executive Chairman of Tigris Pharmaceuticals, Inc. a privately-owned biotech company that is developing new molecules for several cancers and other indications. Also, Mr. Flanzraich is the Chairman of ParinGenix, Inc., another privately owned biotech company, which is developing a unique analog of heparin with low anticoagulant activity for a number of indications. Additionally, Mr. Flanzraich is a founder and a principal of a venture capital firm named Leviathan Biopharma Group, LLC.

Mr. Flanzraich served as the Vice Chairman and President of Ivax Corporation, an international pharmaceutical company, until it was sold to Teva in 2006 for \$10 billion. Earlier he was the Senior Vice President and chief counsel and a member of the Executive Committee of Syntex Corporation, an international pharmaceutical company, that was sold to Roche in 1994 for \$5.3 billion. He also served as the Chairman of North American Vaccine, Inc., which was sold to Baxter International, Inc. in 2000.

Currently, Mr. Flanzraich is also member of the boards of directors of the following public companies: Bellus Health Inc., a biotech company; Chipotle Mexican Grill, a Mexican food chain; Continucare Corporation, a healthcare service provider, and Equity One, Inc., a real estate investment trust. Additionally, he is a member of the Board of Directors of privately-owned Outcomes Health Information Solutions, LLC, a provider of healthcare data retrieval, analytics and management services. Mr. Flanzraich is also a member of the Advisory Board of The Wolfsonian-FIU, a museum of art, design and communication.

Mr. Flanzraich graduated from Harvard College (magna cum laude, Phi Beta Kappa) and from Harvard Law School (magna cum laude). He is married and has two sons.